Morepen Q1 FY27: Commercial CDMO Supplies Start to Show Up in the Numbers

Morepen Laboratories opened FY27 with a quarter that looked less like a recovery and more like proof that its operating model is changing. Revenue for Q1 FY27 rose 34 percent year on year to Rs. 575.31 crore, the company’s highest ever quarterly revenue. Profitability moved even faster. EBITDA grew 207 percent to Rs. 87.72 crore and PAT rose 394 percent to Rs. 56.35 crore. The EBITDA margin expanded to 15.25 percent from 6.65 percent a year ago, a shift that signals operating leverage and a better mix rather than just volume.

The key message in the presentation was “commercial validation.” Morepen’s CDMO journey has moved from development and validation to commercial dispatches, with Rs. 58 crore of commercial CDMO dispatches in the quarter. Alongside this, the company highlighted an Rs. 825 crore CDMO mandate that has now entered commercial supplies. For investors, the importance is not the size of a single quarter’s dispatches, but the implied durability. Management positioned CDMO as long-duration customer programs with recurring revenues and higher margins, supported by audit readiness and global quality systems.

Operating leverage and mix improve the earnings profile

The headline jump in margins sits at the center of the quarter. Morepen described the performance as driven by operational execution, and the bridge appears to be a combination of stronger scale, improved product and customer mix, and tighter operating discipline. Exports were up 111 percent year on year, which the company tied to prioritisation of the customer mix. In APIs, export revenue was up 42 percent, also attributed to better mix and prioritisation.

This matters because the company is trying to reduce the volatility historically associated with commodity API cycles. In the presentation, “Old Morepen” was framed as commodity APIs, commodity pricing, quarterly volatility, and transaction-led business. “Morepen 2.0” was framed as innovation-led manufacturing, long-duration CDMO, recurring customer programs, and more predictable earnings. Q1 FY27 is being presented as the first quarter where that narrative is visible in financial outcomes.

At the segment level, APIs grew 31 percent and medical devices grew 19 percent. Morepen’s API business was described as returning to healthy profitability, with the core franchise stabilising while CDMO becomes the next growth layer. The devices business was positioned as a scalable chronic-care platform anchored by an installed base and recurring consumables.

Note: Segment base values were not provided in the presentation for Q1 FY26 and Q1 FY27, only growth rates.

CDMO moves from promise to commercial scale

The most consequential operational update is that CDMO has progressed into commercial production and dispatch. The presentation laid out a sequence from development to customer audit, validation, order receipt, commercial production, and commercial dispatched, and placed the current period at commercial scale.

Morepen also signaled that the CDMO opportunity is not framed as a one-off. It described the program nature of CDMO as long-duration, recurring, and higher margin. That framing is consistent with the company’s stated intent to move away from transaction-based commodity APIs. If these programs sustain, they can change the quality of earnings through higher visibility and a steadier order cadence.

The company’s regulatory track record is being used as the enabling asset for this transition. Morepen listed multiple global regulators and systems including FDA, EDQM and TGA, along with global audit readiness and GMP-compliant manufacturing. It highlighted “NII 483 observations” across four USFDA inspections in a row. For investors, the practical takeaway is that quality outcomes can influence the pace at which a plant wins and retains global customer programs, particularly in CDMO where customer audits and compliance standards are constant gates to volume ramp-ups.

Capacity and capability roadmap: matching demand with scale

Management anchored the next phase of growth on four pillars: capacity augmentation, global partnerships, capability scaleup, and global compliance. The capacity plan was expressed in terms of kilolitre expansion targets over several years. Capacity stood at 535 KL by Q4 FY26, with step-ups planned to 600 KL by Q2 FY27, 800 KL by Q2 FY28, 1000 KL by FY29, and 1200 KL by FY30.

This staged expansion approach is important because it implies the company expects demand, particularly from CDMO, to grow in a way that justifies larger reactors and throughput. It also signals that management is trying to align investment with customer programs rather than building capacity far ahead of utilisation.

Alongside physical scale, Morepen described an innovation and technology roadmap that starts from its current base in small molecules, process chemistry, commercial APIs and CDMO, and moves toward complex chemistry, advanced intermediates, and high-potency APIs. It also listed emerging areas such as oligos and new modalities, specialty APIs, and difficult-to-make molecules, while noting a selective, capability-led expansion direction. The key investment implication is that a move into more complex chemistries can increase entry barriers and pricing power, but it requires consistent execution, regulatory discipline, and customer qualification.

The sustainability and compliance framing also featured prominently in the platform narrative. The company cited zero liquid discharge and solar initiatives, and described responsible supply supported by exports to over 90 countries. While these points do not translate directly into quarterly financials, they often influence partner selection for global pharmaceutical supply chains.

Medical devices: recurring consumables support a second engine

Morepen’s medical devices business was positioned as a scalable healthcare platform in chronic care. The company highlighted a blood glucose meter installed base of 20 million and 500 million strips per annum, pointing to the consumables engine that can provide recurring usage and better margin visibility. It also highlighted blood pressure monitors and the intent to move toward CGM and premium devices as future growth and portfolio upgrade areas.

With devices growing 19 percent in Q1 FY27, the segment adds diversification to the overall earnings model. It can also reduce reliance on any single driver, especially as CDMO ramps and APIs are being reshaped toward higher-value opportunities. The company’s narrative suggests the devices segment is not being treated as an ancillary business but as a parallel platform with repeat consumption patterns.

What to watch from here

Q1 FY27 sets up a clear theme: execution is starting to show up in the income statement. Revenue reached a quarterly record at Rs. 575.31 crore and profitability rose sharply, with EBITDA at Rs. 87.72 crore and PAT at Rs. 56.35 crore. The magnitude of margin expansion to 15.25 percent implies that mix and operating leverage are becoming more meaningful.

The next questions for investors are about repeatability. The company’s own framing points to three operational tests. First, whether commercial CDMO supplies scale beyond the initial Rs. 58 crore dispatches and convert the Rs. 825 crore mandate into a steady run-rate. Second, whether the API business continues to stay in a healthier profitability zone as capacity is realigned toward higher-value opportunities and export mix improves. And third, whether the devices platform continues to grow with the economics of recurring strips supporting stable contribution.

Morepen’s outlook section described the near term as commercial CDMO supplies, API profitability recovery, and capacity utilisation. Medium term priorities were capacity augmentation, new customer opportunities, and operating leverage. The long term direction was innovation-led manufacturing, global partnerships, and sustainable value creation.

Taken together, the quarter reads as a pivot point. The company is not only reporting higher numbers; it is linking them to a strategic shift from commodity exposure toward program-led manufacturing and platform depth. If execution continues and capacity additions track customer demand, Morepen’s earnings profile could become less volatile and more predictable over time, which is the core promise of the Morepen 2.0 narrative.